THU0185 The value of adalimumab trough levels and clinical assessments in predicting clinical response in patients with established rheumatoid arthritis and an inadequate response to methotrexate

J. Smolen, N. Mostafa, X. Huang, P. Noertersheuser, B. Kluender, K. Chen, J. Kalabic, I. Sainsbury, R. Oerlemans, S. Florentinus, G. Burmester
2018 THURSDAY, 14 JUNE 2018   unpublished
doi:10.1136/annrheumdis-2018-eular.2721 fatcat:jgrzavyr5jdfhd6lcjiehxnuca